Alprazolam, a benzodiazepine, has been studied as a possible treatment for the anxiety- and depression-like components of premenstrual syndrome, but the results of these studies have been inconclusive. Schmidt and colleagues performed a randomized, double-blind, placebo-controlled crossover trial of alprazolam in women with prospectively confirmed premenstrual syndrome.
Women were recruited by newspaper advertisements or physician referral. Twenty women completed the study. A diagnosis of premenstrual syndrome was confirmed through the use of daily self-rating symptom checklists. The women were randomized to receive alprazolam or placebo from day 16 of the menstrual cycle until the onset of menses. Over four menstrual cycles, the alprazolam dose was increased from 0.25 mg to 0.75 mg three times a day. The women completed checklists daily and a battery of psychiatric screening questionnaires twice monthly. Results of these measures in placebo and alprazolam months were then compared.
No differences were found in self-rating scores between alprazolam months and placebo months. Results of psychiatric screening also did not differ between treatment and placebo months, except for a statistically, but not clinically significant, improvement in depression scores during alprazolam treatment.
The authors conclude that no uniform improvement in symptoms of premenstrual syndrome occurs in patients receiving alprazolam, although patients with strong depressive symptoms may have some benefit. (Archives of General Psychiatry, June 1993, vol. 50, p. 467)
COPYRIGHT 1993 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group